Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H AI Stock Analysis
Want to see HK:8049 full AI Analyst Report?
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H (8049) AI Stock Analysis
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H
(HKEX:8049)
The company's exceptional financial strength, characterized by a debt-free balance sheet and robust cash flow generation, is the primary driver of the score. A very low P/E ratio further supports a positive valuation view. These strengths are partially offset by neutral technical indicators, which suggest a lack of immediate upward price momentum despite a generally bullish trend.
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H (8049) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.63B
- Dividend Yield
- ―
- Average Volume (3M)
- 46.44K
- Price to Earnings (P/E)
- 4.9
- Beta (1Y)
- 0.25
- Revenue Growth
- 0.20%
- EPS Growth
- 24.13%
- Country
- Hong Kong
- Employees
- 1,107
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Business Overview & Revenue Model
Company Description
Jilin Province Huinan Changlong Bio-pharmacy Company Limited focuses on the manufacturing and sale of traditional Chinese medicines and various pharmaceutical products within the People's Republic of China. The company's extensive product portfolio i...
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Financial Statement Overview
Summary
The company demonstrates strong financial health with an Income Statement Score of 85, Balance Sheet Score of 92, and Cash Flow Score of 90. The balance sheet is nearly debt-free, cash flow conversion is excellent, and profitability margins are robust, though revenue growth has moderated.
Income Statement
85Very PositiveBalance Sheet
92Very PositiveCash Flow
90Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.11B | 901.87M | 881.16M | 841.54M | 841.59M | 705.46M |
| Gross Profit | 938.82M | 757.67M | 685.25M | 584.05M | 648.03M | 580.00M |
| EBITDA | 332.86M | 294.19M | 236.33M | 226.39M | 231.43M | 206.50M |
| Net Income | 278.44M | 198.88M | 184.25M | 148.21M | 193.56M | 143.28M |
Balance Sheet | ||||||
| Total Assets | 2.73B | 2.67B | 2.53B | 2.32B | 2.37B | 2.07B |
| Cash, Cash Equivalents and Short-Term Investments | 902.41M | 681.45M | 539.03M | 655.59M | 1.03B | 262.25M |
| Total Debt | 399.93K | 400.00K | 72.40M | 80.40M | 400.00K | 400.00K |
| Total Liabilities | 922.64M | 982.74M | 901.49M | 838.44M | 760.54M | 618.56M |
| Stockholders Equity | 1.81B | 1.69B | 1.63B | 1.48B | 1.61B | 1.45B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 300.80M | 208.63M | 284.11M | 192.68M | 122.25M |
| Operating Cash Flow | 0 | 313.24M | 219.65M | 315.95M | 203.99M | 215.09M |
| Investing Cash Flow | 0 | -229.19M | -310.93M | 109.04M | -117.97M | -160.61M |
| Financing Cash Flow | 0 | -176.80M | -25.01M | -186.45M | -27.71M | -25.20M |
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8049, the sentiment is Positive. The current price of 2.91 is above the 20-day moving average (MA) of 2.68, above the 50-day MA of 2.49, and above the 200-day MA of 2.23, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 71.08 is Negative, neither overbought nor oversold. The STOCH value of 80.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8049.
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Peers Comparison
Overall Rating
HK:804979.5Outperform
HK:234874Outperform
HK:106173Outperform
HK:216173Outperform
HK:263370Outperform
HK:256138Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | HKD 1.63B | 4.94 | 15.91% | ― | 0.20% | 24.13% | |
| 74Outperform | HKD 1.36B | 5.02 | 6.78% | 7.00% | 6.55% | 36.62% | |
| 73Outperform | HKD 1.16B | 4.34 | 10.70% | 5.88% | -0.74% | -15.21% | |
| 73Outperform | HKD 1.26B | 6.14 | 18.70% | 11.13% | 6.69% | 2.45% | |
| 70Outperform | HKD 1.75B | 6.09 | 13.26% | 9.83% | -0.47% | -0.40% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 38Underperform | HKD 1.42B | -4.83 | -33.42% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:8049 | Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H | 2.91 | 0.98 | 50.93% | |
| HK:1061 | Essex Bio-Technology | 2.04 | -2.23 | -52.25% | |
| HK:2161 | JBM (Healthcare) Ltd. | 1.53 | -1.15 | -42.87% | |
| HK:2348 | Dawnrays Pharmaceutical Holdings Ltd. | 0.90 | -0.20 | -18.26% | |
| HK:2633 | Jacobson Pharma Corporation Limited | 0.92 | -0.43 | -31.85% | |
| HK:2561 | VISEN Pharmaceuticals | 12.46 | -20.94 | -62.69% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 19, 2026
